Non-culprit lesion revascularization in patients with acute myocardial infarction: A systematic review and meta-analysis
Keywords:
Acute myocardial infarction, myocardial revascularization, coronary artery disease, major adverse cardiac eventsAbstract
Introduction: Multivessel disease is present in approximately 50% of patients experiencing acute myocardial infarction. Initially, revascularization of the culprit lesion during primary PCI was exclusively recommended for patients in cardiogenic shock.
Objective: The aim of this study was to assess whether complete revascularization is associated with reduced cardiovascular mortality and adverse cardiovascular events.
Material and Methods: A search was conducted in the following bibliographic databases: MEDLINE, Cochrane, Embase, ISI Web of Science, and CENTRAL (Cochrane Central Register of Controlled Trials), SciELO. The search was performed in February 2024, without a time limit, and was updated monthly until June 2024. Randomized controlled trials or meta-analyses of randomized controlled trials were selected, with no restrictions on publication year or language that included the following terms: myocardial revascularization, ST-segment elevation myocardial infarction, coronary artery disease, and coronary stenosis.
Results: The systematic review and meta-analysis included seven randomized controlled trials involving 6597 patients, comparing complete revascularization with culprit-only percutaneous coronary intervention. The complete revascularization strategy was associated with a significantly lower risk of major adverse cardiovascular events (RR= 0.50, 95% CI: 0.56-0.74; p<0.001, I2= 0%) and repeated revascularizations (RR=0.32, 95% CI: 0.24-0.42; p<0.001, I2= 42%).
Conclusions: Our findings demonstrate that revascularization of non-culprit lesions in patients with STEMI is associated with a significant reduction in major adverse cardiovascular events, repeated revascularizations, and the composite outcome of cardiac death and non-fatal myocardial infarction.
Downloads
References
1. WHO. Enfermedad pulmonar obstructiva crónica (EPOC) [Internet]. Geneva: WHO; 2023 [Citado 22/07/2024]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2. Sanabria-Montañez C, Cabrejos Polo J, Olortegui Yzu AR, San Juan Lezama H, Lama More MA, Villamonte Blas R, et al. Patrones de costos de atención a pacientes con enfermedades isquémicas del corazón en el Instituto Nacional Cardiovascular, 2019. Anales de la Facultad de Medicina. 2022;83(2):104-11.
3. Rohani C, Jafarpoor H, Mortazavi Y, Esbakian B, Gholinia H. Mortality in patients with myocardial infarction and potential risk factors: A five-year data analysis. ARYA Atheroscler. 2022;18(3):1-8.
4. Coughlan JJ, Ibáñez B. Reperfusion in ST-elevation myocardial infarction: delays have dangerous ends. Eur Heart J. 2023;44(6):529-31.
5. Backhaus SJ, Kowallick JT, Stiermaier T, Lange T, Koschalka A, Navarra JL, et al. Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction. Clin Res Cardiol. 2020;109(3):339-49.
6. Dai J, Fang C, Zhang S, Li L, Wang Y, Xing L, et al. Frequency, Predictors, Distribution, and Morphological Characteristics of Layered Culprit and Nonculprit Plaques of Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions. 2020;13(10):e009125.
7. Li R, Loh K, Loo G, Tai BC, Lee CH. Culprit versus non-culprit lesion related adverse cardiac events in patients with obstructive sleep apnoea. Heart Asia. 2013;5(1):162-7.
8. Sagris M, Apostolos A, Theofilis P, Ktenopoulos N, Katsaros O, Tsalamandris S, et al. Myocardial Ischemia–Reperfusion Injury: Unraveling Pathophysiology, Clinical Manifestations, and Emerging Prevention Strategies. Biomedicines. 2024;12(4):802.
9. Mani A, Ojha V, Sivadasanpillai H, Sasidharan B, Ganapathi S, Valaparambil AK. Culprit Lesion Morphology on Optical Coherence Tomography in ST-elevation Myocardial Infarction vs Non ST-elevation Myocardial Infarction - A Systematic Review of 7526 Patients. J Saudi Heart Assoc. 2023;35(1):40-9.
10. Michaud K, Basso C, d’Amati G, Giordano C, Kholová I, Preston SD, et al. Diagnosis of myocardial infarction at autopsy: AECVP reappraisal in the light of the current clinical classification. Virchows Arch. 2020;476(2):179-94.
11. Dziewierz A, Siudak Z, Rakowski T, Zasada W, Dubiel JS, Dudek D. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry). Am J Cardiol. 2010;106(3):342-7.
12. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e4-17.
13. Stähli BE., Varbella F, Linke , Schwarz B, Felix SB, Seiffert M, et al. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine. 2023;389(15):1368-79.
14. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med. 2017;376(13):1234-44.
15. Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.
16. Manual Cochrane de revisiones sistemáticas de intervenciones [Internet]. London: Cochrane Training; 2011 [Citado 22/07/2024]. Disponible en: https://training.cochrane.org/es/manual-cochrane-de-revisiones-sistem%C3%A1ticas-de-intervenciones
17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Esp Cardiol. 2021;74(9):790-9.
18. Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent. 2004;6(3-4):128-33.
19. Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart. 2010;96(9):662-7.
20. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115-23.
21. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65(10):963-72.
22. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019;381(15):1411-21.
23. Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. JAMA Cardiol. 2020;5(8):881-8.
24. Levett JY, Windle SB, Filion KB, Cabaussel J, Eisenberg MJ. Meta-Analysis of Complete versus Culprit-Only Revascularization in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. Am J Cardiol. 2020;135:40-9.
25. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665-71.
26. Pinilla-Echeverri N, Mehta SR, Wang J, Lavi S, Schampaert E, Cantor WJ, et al. Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography Substudys. Circ Cardiovasc Interv. 2020;13(7):e008768.
27. Omer MA, Brilakis ES, Kennedy KF, Alkhouli M, Elgendy IY, Chan PS, et al. Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. JACC: Cardiovascular Interventions. 2021;14(10):1067-78.
28. Maqsood MH, Tamis-Holland JE, Rao SV, Stone GW, Bangalore S. Culprit-Only Revascularization, Single-Setting Complete Revascularization, and Staged Complete Revascularization in Acute Myocardial Infarction: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials. Circulation: Cardiovascular Interventions. 2024;17(7):e013737.
29. Denormandie P, Simon T, Cayla G, Steg PG, Montalescot G, Durand-Zaleski I, et al. Compared Outcomes of ST-Segment–Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial. Circulation: Cardiovascular Interventions. 2021;14(11):e011314.
30. Elbadawi A, Sedhom R, Dang AT, Gad MM, Rahman F, Brilakis ES, et al. Fractional flow reserve versus angiography alone in guiding myocardial revascularisation: a systematic review and meta-analysis of randomised trials. Heart. 2022;108(21):1699-706.
31. Mol JQ, Volleberg RHJA, Belkacemi A, Hermanides RS, Meuwissen M, Protopopov AV, et al. Fractional Flow Reserve–Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction. JAMA Cardiology. 2023;8(11):1013-21.
32. Puymirat , Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. New England Journal of Medicine. 2021;385(4):297-308.
33. van der Hoeven NW, Janssens GN, de Waard GA, Everaars H, Broyd CJ, Beijnink CWH, et al. Temporal Changes in Coronary Hyperemic and Resting Hemodynamic Indices in Nonculprit Vessels of Patients With ST-Segment Elevation Myocardial Infarction. JAMA Cardiol. 2019;4(8):736-44.
34. Cerrato E, Mejía-Rentería H, Dehbi HM, Ahn JM, Cook C, Dupouy P, et al. Revascularization Deferral of Nonculprit Stenoses on the Basis of Fractional Flow Reserve: 1-Year Outcomes of 8,579 Patients. JACC Cardiovasc Interv. 2020;13(16):1894-903.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Habanera de Ciencias Médicas
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the content of this magazine is in Open Access, distributed according to the terms of the Creative Commons Attribution-Noncommercial 4.0 License that allows non-commercial use, distribution and reproduction without restrictions in any medium, provided that the primary source is duly cited.
Download PDF
